Detailed Narrative
Explosive Growth and Margin Expansion
Sai Life reported a 77% YoY revenue jump to ₹496 crores, underpinned by a 113% surge in the CDMO segment. This scale led to significant operating leverage, with EBITDA margins expanding from 11% to 25% YoY. Management is confident that as revenues continue to scale, they can reach a steady-state EBITDA margin of 28-30%.
Aggressive Capacity Roadmap
The company is in the midst of a massive expansion phase, targeting an 80% increase in manufacturing capacity by 2027. This includes adding two new production blocks by the second half of next year. Furthermore, Process R&D capacity is set to double by next year, and Discovery space will increase by 30% by the end of FY26 to support complex integrated programs.
Strategic Pivot to New Modalities
Sai Life is moving beyond traditional small molecules into high-value modalities including ADCs, oligonucleotides, peptides, and lipids. Management noted they are already working on late-phase commercial assets for ADCs and are 'fairly far ahead' in oligonucleotides. These modalities are expected to be key drivers of future revenue and margin profile.
China Plus One and IP Security
Geopolitical shifts are providing a tailwind as global pharma innovators seek to diversify supply chains away from China. Management highlighted that IP concerns in China, where local firms are becoming competitors in discovery, are driving customers toward Indian partnerships. They believe this is a long-term structural shift that will take years to fully play out.
Pipeline Dynamics and Clinical Risks
While the overall business is growing, the late-stage pipeline saw some volatility, with the number of Phase III/pre-registration molecules dropping to 6 from a previous 10. This was a net result of two molecules moving to commercial stage and others being dropped due to clinical trial failures. Management emphasized that such failures are an inherent risk in the CDMO model and outside their direct control.